1. Home
  2. RNG vs NVCR Comparison

RNG vs NVCR Comparison

Compare RNG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNG
  • NVCR
  • Stock Information
  • Founded
  • RNG 1999
  • NVCR 2000
  • Country
  • RNG United States
  • NVCR Switzerland
  • Employees
  • RNG N/A
  • NVCR N/A
  • Industry
  • RNG EDP Services
  • NVCR Medical/Dental Instruments
  • Sector
  • RNG Technology
  • NVCR Health Care
  • Exchange
  • RNG Nasdaq
  • NVCR Nasdaq
  • Market Cap
  • RNG N/A
  • NVCR 1.9B
  • IPO Year
  • RNG 2013
  • NVCR 2015
  • Fundamental
  • Price
  • RNG $26.67
  • NVCR $17.44
  • Analyst Decision
  • RNG Buy
  • NVCR Buy
  • Analyst Count
  • RNG 13
  • NVCR 6
  • Target Price
  • RNG $34.46
  • NVCR $32.83
  • AVG Volume (30 Days)
  • RNG 1.0M
  • NVCR 861.0K
  • Earning Date
  • RNG 05-08-2025
  • NVCR 04-24-2025
  • Dividend Yield
  • RNG N/A
  • NVCR N/A
  • EPS Growth
  • RNG N/A
  • NVCR N/A
  • EPS
  • RNG N/A
  • NVCR N/A
  • Revenue
  • RNG $2,400,395,000.00
  • NVCR $621,711,000.00
  • Revenue This Year
  • RNG $5.94
  • NVCR $2.90
  • Revenue Next Year
  • RNG $5.98
  • NVCR $10.47
  • P/E Ratio
  • RNG N/A
  • NVCR N/A
  • Revenue Growth
  • RNG 8.99
  • NVCR 18.27
  • 52 Week Low
  • RNG $20.59
  • NVCR $14.17
  • 52 Week High
  • RNG $42.19
  • NVCR $34.13
  • Technical
  • Relative Strength Index (RSI)
  • RNG 62.20
  • NVCR 48.61
  • Support Level
  • RNG $25.28
  • NVCR $16.19
  • Resistance Level
  • RNG $26.33
  • NVCR $18.52
  • Average True Range (ATR)
  • RNG 0.78
  • NVCR 0.85
  • MACD
  • RNG 0.43
  • NVCR 0.06
  • Stochastic Oscillator
  • RNG 92.07
  • NVCR 54.82

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: